1. INDICATED FOR THE TREATMENT OF ADULTS WITH PERSISTENT/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH), (WHO GROUP 4) AFTER SURGICAL TREATMENT, OR INOPERABLE CTEPH, TO IMPROVE EXERCISE CAPACITY AND WHO FUNCTIONAL CLASS.
2. ADULTS WITH PULMONARY ARTERIAL HYPERTENSION, (WHO GROUP 1), TO IMPROVE EXERCISE CAPACITY, WHO FUNCTIONAL CLASS AND TO DELAY CLINICAL WORSENING.
EFFICACY WAS SHOWN IN PATIENTS ON MONOTHERAPY OR IN COMBINATION WITH ENDOTHELIN RECEPTOR ANTAGONISTS OR PROSTANOIDS, PREDOMINATELY IN PATIENTS WITH WHO FUNCTIONAL CLASS II-III AND ETIOLOGIES OF IDIOPATHIC OR HERITABLE PAH (61%) OR PAH ASSOCIATED WITH CONNECTIVE TISSUE DISEASES (25%).
RECOMMENDED STARTING DOSAGE: 1 MG 3 TIMES A DAY. IF DEVELOPS HYPOTENSION, REDUCE STARTING DOSE TO 0.5 MG TDS. UP-TITRATE THE DOSE BY 0.5 MG TAKEN THREE TIMES A DAY. DOSE INCREASES SHOULD BE NO SOONER THAN 2 WEEKS APART TO MAX. OF 2.5 MG TDS. IF AT ANY TIME, THE PATIENT HAS SYMPTOMS OF HYPOTENSION, DECREASE THE DOSAGE BY 0.5 MG TDS.